Part-Time
Analytics & Behavior Change Engineering New Grad
Conversion
Updated on 8/1/2026
CVS Health
10,001+ employees
Healthcare, insurance, PBM, and retail pharmacy
No salary listed
Company Historically Provides H1B Sponsorship
New York, NY, USA
Hybrid
Hybrid work allows office and home working; specific office locations will be confirmed with the recruiter.
 AI & Machine Learning (1) |
|---|
Get referred to CVS Health
See people who can refer or advise you
- Currently participating in the Analytics & Behavior Change Internship Program within the discipline specified on the requisition.
- Meet the educational requirements by currently pursuing a Master's degree program with an expected graduation date between December 2026 and June 2027.
- Apply engineering expertise within the Analytics & Behavior Change team across software engineering, machine learning engineering, or data engineering opportunities.
- Demonstrate problem-solving and critical-thinking ability.
- Communicate technical concepts and their implications clearly to technical and non-technical audiences in written and verbal form.
CVS Health operates as a diversified health services company in the United States, organized into Health Care Benefits, Pharmacy & Consumer Wellness, and Health Services. Its offerings include medical insurance products, retail and mail-order prescription drugs, and pharmacy benefit management (PBM) services, all connected through its integrated platform. By combining insurance, retail pharmacy, PBM, and health solutions, CVS Health coordinates care and controls costs across touchpoints for individuals, employers, and government programs. The company aims to lower health care costs while improving access and health outcomes for customers.
Company Size
10,001+
Company Stage
IPO
Headquarters
Woonsocket, Rhode Island
Founded
1963
Get referred to CVS Health
See people who can refer or advise you
Simplify's Take
What believers are saying
- Aetna margins recovery drove Q1 2026 operating income up $1.2B year-over-year
- Raised full-year 2026 EPS guidance to $7.30–$7.50 after Q1 revenue hit $100.4B
- Exited ACA loss plans eliminating $350M–$400M annual losses, improving medical benefit ratio to 87.3%
What critics are saying
- CMS Medicare Advantage rate shock forces 5–10% membership trim with high margin erosion in 6–12 months
- House Judiciary Committee alleges CVS Caremark blocks innovation via network controls, risking regulatory action in 12–18 months
- Amazon Pharmacy and Walmart undercut CVS's $32B quarterly retail revenue base with high market-share gains in 12–24 months
What makes CVS Health unique
- Integrates 9,000 retail pharmacies, 1,000 clinics, and 88M PBM members for 185M consumer reach
- Launches Health100 AI platform in 2026 to proactively anticipate member health needs continuously
- Resolves 75% of pharmacy interactions via AI assistant, cutting phone call costs significantly
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Company Equity
Wellness Program
Professional Development Budget
Paid Vacation
Paid Holidays
Company News
CVS Health closed at $106.89 on 23 July 2026, up 78.2% over the past year. The company pays a quarterly dividend of $0.665, or $2.66 annually, yielding roughly 2.5%. The payout has remained frozen for 10 consecutive quarters, though CVS has never cut its dividend in 27 years. Free cash flow of $7.8 billion covers the dividend more than twice. Q1 2026 marked the fifth straight earnings beat, with adjusted EPS of $2.57 topping consensus by 16%. Revenue reached $100.43 billion, up 6.2% year over year. Risks include a leveraged balance sheet with $175 billion in liabilities and $3.12 billion in annual interest expense. CVS absorbed a $5.7 billion goodwill impairment in FY 2025 and posted a $3.2 billion operating loss in Q3 2025. Insiders sold $323.7 million worth of shares over the past three months.
Two large-cap stocks show strong growth potential whilst one faces headwinds, according to StockStory analysis. CVS Health, with a market capitalisation of $137.1 billion, struggles with slowing growth. Its revenue increased just 6.3% annually over two years, underperforming peers. Wall Street expects flat revenue over the next 12 months. Earnings per share fell 1.5% annually over five years despite revenue growth. The stock trades at $107.70, or 13.9 times forward price-to-earnings. Cloudflare emerges as a buy candidate. The network security provider posted average billings growth of 34.2% over the past year. Analysts project 28.4% revenue growth for the coming year. The company trades at $276.18 per share, or 32.1 times forward price-to-sales. Rocket Lab also features on the buy list. The small satellite launch provider has reached a market capitalisation of $40.45 billion.
CVS Health has opened its first pharmacy-focused location in Houston at 8503A Gulf Freeway. The company plans to launch nearly 20 such locations across the US to increase access to pharmacy care. These smaller pharmacies, averaging around 3,000 square feet, feature full-service pharmacies with customised over-the-counter product selections. The Houston opening follows similar launches in Birmingham, Chicago, Detroit, and Washington, DC. Two additional pharmacy-focused locations are planned for the greater Houston area within the next year. The move comes as CVS's 2025 Rx Report showed 80% of patients prefer face-to-face pharmacy care, with 48% willing to switch pharmacies if limited to digital-only options. The pharmacy-focused format joins CVS's existing portfolio, which includes traditional stores, locations inside Target and Schnucks, and sites with MinuteClinic facilities.
CVS Health is set to announce its second-quarter 2026 earnings on 5 August before market open. Analysts expect the company to report adjusted earnings per share of $1.86, up 2.8% year-over-year. The Woonsocket, Rhode Island-based healthcare company has beaten Wall Street's bottom-line estimates in each of the past four quarters. For the full fiscal year 2026, analysts predict adjusted EPS of $7.44, representing a 10.2% increase from fiscal 2025. CVS shares have surged 57.9% over the past 52 weeks, outperforming the S&P 500's 20.3% gain. In May, the company raised its full-year 2026 guidance to $7.30-$7.50 per share, driven by stronger medical cost controls at Aetna and improved profitability at Caremark. Analysts maintain a "Strong Buy" rating on the stock, with an average price target of $107.08.
CVS Health shares surged 57% between 30 June 2025 and 1 July 2026, but the turnaround signals were visible well before the rally. Management explicitly outlined its recovery plan for the struggling Aetna insurance unit, which faced operating losses in 2024. The finance chief quantified the opportunity, stating there were "$3, $4 more of embedded adjusted EPS" if Aetna returned to target margins. The strategy involved trimming Medicare Advantage membership by 5% to 10% to eliminate unprofitable plans. The first concrete proof arrived in fiscal Q1 2025, when the Health Care Benefits segment's operating income jumped by over $1.2 billion year-over-year. The medical benefit ratio improved to 87.3%. CVS subsequently raised its full-year 2025 guidance and exited money-losing ACA exchange plans, eliminating $350 million to $400 million in projected annual losses.